Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Work In Process (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Work In Process for 15 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 18.45% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, up 18.45% year-over-year, with the annual reading at $3.3 million for FY2025, 18.45% up from the prior year.
  • Work In Process for Q4 2025 was $3.3 million at Harvard Bioscience, up from $2.3 million in the prior quarter.
  • The five-year high for Work In Process was $4.6 million in Q3 2023, with the low at $1.6 million in Q2 2025.
  • Average Work In Process over 5 years is $3.4 million, with a median of $3.5 million recorded in 2021.
  • The sharpest move saw Work In Process rose 20.7% in 2023, then crashed 52.79% in 2025.
  • Over 5 years, Work In Process stood at $3.4 million in 2021, then increased by 10.73% to $3.8 million in 2022, then increased by 10.91% to $4.2 million in 2023, then crashed by 34.24% to $2.8 million in 2024, then grew by 18.45% to $3.3 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $3.3 million, $2.3 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.